| 摘要 |
FIELD: medicine, molecular biology, biochemistry. ^ SUBSTANCE: invention relates to the complete sequences encoding a novel protein, urocortin-III (Isp-III) of the family of corticotropin-releasing factors wherein these sequences are prepared from human and mouse genome DNA. The main feature of Isp-III is its enhanced affinity to CRF-2-alpha or CRF-2-beta receptors as compared with CRF-1 receptors that determines possibility for its functioning as CRF-2 receptors agonist. Synthetic analogs of Isp-III retaining ability of native protein to the selective interaction with CRF-2 are obtained. Invention proposes using the novel protein and its analogs as component of pharmaceutical compositions that are designated for treatment of pathophysiological states associated with necessary for activation of CRF-2, in particular, the congested cardiac insufficiency, gastrointestinal tract dysfunction, diabetes mellitus, migraine and other diseases. ^ EFFECT: valuable medicinal properties of agent. ^ 14 cl, 10 dwg, 3 tbl, 16 ex |
